

# CITATION REPORT

List of articles citing

## Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.

DOI: 10.1007/s11523-021-00857-8  
Targeted Oncology, 2021, 17, 69.

**Source:** <https://exaly.com/paper-pdf/125633955/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	11
20	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
19	New Mechanisms of Genomic Escape From Noncovalent BTK Inhibitors.. <i>HemaSphere</i> , <b>2022</b> , 6, e0715	0.3	
18	Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2807	5.1	2
17	Zanubrutinib for the Treatment of B-cell Malignancies. <i>Touch Reviews in Oncology &amp; Haematology</i> , <b>2022</b> , 18, 44		
16	Expression and Clinical Significance of Th1/Th2/Th17 Cytokines and Lymphocyte Subsets in PCNSL. <i>Journal of Inflammation Research</i> , Volume 15, 3815-3828	4.8	
15	Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Volume 16, 3225-3239		0
14	Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics. 13,		0
13	Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. <b>2022</b> , 8, e10928		0
12	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. <b>2022</b> , 15,		1
11	Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib.		1
10	Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations. <b>2022</b> , 27, 7451		1
9	Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. <b>2022</b> , 3,		1
8	Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.		0
7	A Multidisciplinary Approach to Managing BTK Inhibitor Toxicity in Lymphoma and Chronic Lymphocytic Leukemia. <b>2023</b> ,		0
6	Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS. <b>2023</b> , 28, 1205		0
5	Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis: an open-label, phase 2 trial.		0

- 4 Bruton Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. **2023**, 28, 2400
- 3 Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings.
- 2 Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors. 1-13
- 1 Targeted therapy. **2023**, 205-411